Hepatocellular carcinoma (HCC) ranks fifth among the common cancers worldwide. Hepatocarcinogenesis is a multiple-phases process, which involves changes in cellular genomes including high cell proliferation.In this study, we aimed to evaluate the relationship of NGAL level at the time of diagnosis with mortality in patients diagnosed with HCC.
Material and Methods
A total of 35 patients who developed HCC on the ground of HBV(+) and 30 healthy subjects were included in the study. Barcelona Clinic Liver Cancer (BCLC), Okuda staging system, and Milan criteria were used for staging of the patients with HCC.
The mean age of all patients was 59.54 ± 11.57 years. Seventeen (48.6%) HCC patients died during 1-year follow-up. Survival of the patients who met the Milan criteria was longer (log-rank (Mantel-Cox) test, χ2 = 5.353, p = 0.021). Kaplan-Meier curve was drawn for NGAL cut-off value, mortality was found to be higher in patients with a NGAL level higher than 217.50 (log-rank (Mantel-Cox) test, χ2 = 15.540, p < 0.001).
In this study, we found that high levels of NGAL at the time of diagnosis were associated with poor prognosis in HCC patients.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30.
Altekruse SF, McGlynn KA, Reichman ME. Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005. J Clin Oncol. 2009;27(9):1485–91.
Forner A, Llovet JM, Bruix J. Hepatocellularcarcinoma. Lancet. 2012;379(9822):1245.
Huang YH, Wu JC, Chen CH, Chang TT, Lee PC, Chau GY, et al. Comparison of recurrence after hepatic resection in patients with hepatitis B vs. hepatitis C-related small hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int. 2005;25(2):236–41.
Mehmet A, Dertli R. Serum soluble TWEAK concentration is decreased in patients with hepatocellular cancer and low blood levels of sTWEAK are associated with poor survival. Int J Hematol Oncol. 27(2):118–26.
Cabiati M, Gaggini M, Cesare MM, Caselli C, De Simone P, Filipponi F, et al. Osteopontin in hepatocellular carcinoma: a possible biomarker for diagnosis and follow-up. Cytokine. 2017;99:59–65.
Rodvold JJ, Mahadevan NR, Zanetti M. Lipocalin 2 in cancer: when good immunity goes bad. Cancer Lett. 2012;316(2):132–8.
Li C, Chan YR. Lipocalin 2 regulation and its complex role in inflammation and cancer. Cytokine. 2011;56(2):435–41.
Jin D, Zhang Y, Chen X. Lipocalin 2 deficiency inhibits cell proliferation, autophagy, and mitochondrial biogenesis in mouse embryonic cells. Mol Cell Biochem. 2011;351(1-2):165–72.
Leng X, Wu Y, Arlinghaus RB. Relationships of lipocalin 2 with breast tumorigenesis and metastasis. J Cell Physiol. 2011;226(2):309–14.
Lin H-H, Liao C-J, Lee Y-C, Hu K-H, Meng H-W, Chu S-T. Lipocalin-2-induced cytokine production enhances endometrial carcinoma cell survival and migration. Int J Biol Sci. 2011;7(1):74–86.
Lim R, Ahmed N, Borregaard N, Riley C, Wafai R, Thompson EW, et al. Neutrophil gelatinase-associated lipocalin (NGAL) an early-screening biomarker for ovarian cancer: NGAL is associated with epidermal growth factor-induced epithelio-mesenchymal transition. Int J Cancer. 2007;120(11):2426–34.
Furutani M, Arii S, Mizumoto M, Kato M, Imamura M. Identification of a neutrophil gelatinase-associated lipocalin mRNA in human pancreatic cancers using a modified signal sequence trap method. Cancer Lett. 1998;122(1):209–14.
Kubben FJ, Sier CF, Hawinkels LJ, Tschesche H, van Duijn W, Zuidwijk K, et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer. 2007;43(12):1869–76.
Barresi V, Vitarelli E, Bonetti LR, Tuccari G, Barresi G. Diagnostic value of neutrophil gelatinase-associated lipocalin (NGAL) immunoexpression in follicular-patterned lesions of the thyroid gland. Virchows Archiv. 2012;460(3):319–25.
Ozemir IA, Aslan S, Eren T, Bayraktar B, Bilgic C, Isbilen B, et al. The diagnostic and prognostic significance of serum neutrophil gelatinase-associated lipocalin levels in patients with colorectal cancer. Chirurgia (Bucharest, Romania: 1990). 2016;111(5):414–21.
Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002;10(5):1033–43.
Patil MA, Chua M-S, Kuang-Hung P, Lin R, Lih C-J, Cheung S-T, et al. An integrated data analysis approach to characterize genes highly expressed in hepatocellular carcinoma. Oncogene. 2005;24(23):3737.
Lee E-K, Kim H-J, Lee K-J, Lee H-J, Lee J-S, Kim D-G, et al. Inhibition of the proliferation and invasion of hepatocellular carcinoma cells by lipocalin 2 through blockade of JNK and PI3K/Akt signaling. Int J Oncol. 2011;38(2):325–33.
Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment study of 850 patients. Cancer. 1985;56(4):918–28.
Llovet JM, Brú C, Bruix J, editors. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in liver disease; 1999: © 1999 by Thieme Medical Publishers, Inc.
Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–700.
Stejskal D, Karpíšek M, Humenanska V, Hanulova Z, Stejskal P, Kusnierova P, et al. Lipocalin-2: development, analytical characterization, and clinical testing of a new ELISA. Horm Metab Res. 2008;40(06):381–5.
Giasson J, Hua Li G, Chen Y. Neutrophil gelatinase-associated lipocalin (NGAL) as a new biomarker for non-acute kidney injury (AKI) diseases. Inflamm Allergy Drug Targets (Formerly Current Drug Targets-Inflammation & Allergy). 2011;10(4):272–82.
Mir SU, Jin L, Craven RJ. Neutrophil gelatinase-associated lipocalin (NGAL) expression is dependent on the tumor-associated sigma-2 receptor S2RPgrmc1. J Biol Chem. 2012;287(18):14494–501.
Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle. 2009;8(15):2347–52.
Bouchet S, Bauvois B. Neutrophil gelatinase-associated lipocalin (NGAL), pro-matrix metalloproteinase-9 (pro-MMP-9) and their complex pro-MMP-9/NGAL in leukaemias. Cancers. 2014;6(2):796–812.
Zhang Y, Fan Y, Mei Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. Cancer Epidemiol. 2012;36(5):e294–e9.
Chuma M, Sakamoto M, Yamazaki K, Ohta T, Ohki M, Asaka M, et al. Expression profiling in multistage hepatocarcinogenesis: identification of HSP70 as a molecular marker of early hepatocellular carcinoma. Hepatology. 2003;37(1):198–207.
Wang YP, Yu GR, Lee MJ, Lee SY, Chu IS, Leem SH, et al. Lipocalin-2 negatively modulates the epithelial-to-mesenchymal transition in hepatocellular carcinoma through the epidermal growth factor (TGF-beta1)/Lcn2/Twist1 pathway. Hepatology. 2013;58(4):1349–61.
Jayaraman A, Roberts KA, Yoon J, Yarmush DM, Duan X, Lee K, et al. Identification of neutrophil gelatinase-associated lipocalin (NGAL) as a discriminatory marker of the hepatocyte-secreted protein response to IL-1β: a proteomic analysis. Biotechnol Bioeng. 2005;91(4):502–15.
Cowland JB, Sørensen OE, Sehested M, Borregaard N. Neutrophil gelatinase-associated lipocalin is up-regulated in human epithelial cells by IL-1β, but not by TNF-α. J Immunol. 2003;171(12):6630–9.
Moss SF, Blaser MJ. Mechanisms of disease: inflammation and the origins of cancer. Nat Clin Pract Oncol. 2005;2(2):90–7 quiz 1 p following 113.
Nuntagowat C, Leelawat K, Tohtong R. NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation. Clin Exp Metastasis. 2010;27(5):295–305.
Duvillard L, Ortega-Deballon P, Bourredjem A, Scherrer M-L, Mantion G, Delhorme J-B, et al. A case–control study of pre-operative levels of serum neutrophil gelatinase-associated lipocalin and other potential inflammatory markers in colorectal cancer. BMC Cancer. 2014;14(1):912.
Friedl A, Stoesz S, Buckley P, Gould M. Neutrophil gelatinase-associated lipocalin in normal and neoplastic human tissues. Cell type-specific pattern of expression. Histochem J. 1999;31(7):433–41.
Di Carlo A. The enigmatic role of lipocalin 2 in human cancer. The multifunctional protein neutrophil gelatinase-associated lipocalin (NGAL) and its ambiguous role in human neoplasias. Prevent Res. 2012;2.
Moniaux N, Chakraborty S, Yalniz M, Gonzalez J, Shostrom VK, Standop J, et al. Early diagnosis of pancreatic cancer: neutrophil gelatinase-associated lipocalin as a marker of pancreatic intraepithelial neoplasia. Br J Cancer. 2008;98(9):1540–7.
Tong Z, Wu X, Ovcharenko D, Zhu J, Chen C-S, Kehrer JP. Neutrophil gelatinase-associated lipocalin as a survival factor. Biochem J. 2005;391(2):441–8.
This study was conducted in accordance with the ethical standards of the Declaration of Helsinki. The ethical approval was received from the ethical committee of Necmettin Erbakan University Meram Medical Faculty.
Conflict of Interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Dertli, R., Biyik, M., Yolacan, R. et al. May Neutrophil Gelatinase-Associated Lipocalin (NGAL) Level Predict Mortality in Patients with Hepatocellular Carcinoma (HCC)?. J Gastrointest Canc 51, 932–938 (2020). https://doi.org/10.1007/s12029-019-00323-9
- ords: Hepatocellular carcinoma
- Neutrophil gelatinase-associated lipocalin